Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative on Risks of Lead Exposure for Pregnant Women
Lead exposure is a pervasive health threat which, even at low levels, can cause behavioral and learning disabilities, hyperactivity and lower IQ in children. In adults, it can result in difficulty becoming pregnant and maintaining a healthy pregnancy, reduced fertility, as well as hypertension and kidney dysfunction. It is estimated that in the US, 1 in every 100 women of childbearing age has a blood lead level above the current reference value of 5 µg/dL.
“Since news of the lead in water crisis in
Magellan’s program also featured recommendations from Jeanne Hewitt PhD, RN Director, Community Engagement at the
Discussing how obstetricians can respond if they identify lead poisoning, Dr. Brown commented, “The first and most important step is to find the source of the lead and eliminate it. It is also critical to focus on the mother’s nutritional status – anemia and other deficiencies can worsen the effects of lead exposure. Finally, it’s important to educate Mom on the sources of lead, so that they can bring their newborns home to a lead-free environment.”
Magellan’s Lead in Pregnancy initiative is scheduled to run throughout the spring and summer, culminating during Women’s Health Quarter at the end of the year. The company will be hosting webinars and local educational events across the country, including mobile blood lead testing, in addition to offering introductory programs designed to help obstetricians start to perform lead screening as part of the services they offer to their patients. For more information, visit: www2.magellandx.com/ob.
Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. A business unit of
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
John A. KraeutlerChairman, Chief Executive Officer Meridian Bioscience, Inc.Phone: 513.271.3700 Email: firstname.lastname@example.org